Simulations Plus 2021

“For Biotech companies, finding strategic partnerships is a necessity in streamlining our development programs to save time and money. Simulations Plus nimbly partnered on a program to not only develop a PBPK model, but to also develop a DDI regulatory roadmap that informed our regulatory approach towards NDA filing and helped to design the next steps of our program. Their knowledge of the area and ease of partnering exceeded my expectations.”

Sr. Vice President, Pharmaceutical Sciences
“I’d like to give some feedback regarding the excellent prediction work that you performed previously. We have received the results from the clinical phase 1b cohort now and have been able to compare the test item concentrations to those predicted in the model that you created. The predictions are really amazingly accurate!”
Head of Nonclinical Development
“Just wanted to drop a quick note and take the opportunity to highlight the excellent software application support the team has provided for GastroPlus. I really don’t think I would have got to where we have on my own but feel much better positioned now to use some of these additional features in the software. The team has excellent customer focus, and I really like the style and manner in which you interact with the user.”
Lead Specialist
“Often clients are fast and furious to send complaint notes to the CRO, but silent when things are going well. Good work equally needs appreciation & recognition. I am pleased to tell you that I am very happy with the progress of our project at Simulations Plus.”
Sr. Director, Translational Drug Development
2021
November 30, 2021

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Expanding access to high-quality medication for people in need Read More

March 3, 2021

Hosts The Inaugural 2021 MIDD+ Scientific Conference

Hosts The Inaugural 2021 MIDD+ Scientific Conference

Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More

2020
September 15, 2020

Releases ADMET Predictor® Version 10.0 (APX™)

Releases ADMET Predictor® Version 10.0 (APX™)

Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More

August 10, 2020

Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More

April 1, 2020

Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More

January 6, 2020

Grace Fraczkiewicz Celebrates 20 Years of Service

Grace Fraczkiewicz Celebrates 20 Years of Service

In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About her Journey

2018
August 6, 2018

Robert Fraczkiewicz Celebrates 20 Years of Service

Robert Fraczkiewicz Celebrates 20 Years of Service

In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About his Journey

June 26, 2018

Simulations Plus Names Shawn O’Connor as CEO

Simulations Plus Names Shawn O’Connor as CEO

Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More

February 1, 2018

S+pKa Model Wins SAMPL6 pKa Challenge

S+pKa Model Wins SAMPL6 pKa Challenge

Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More

2017
June 1, 2017

DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More

2016
October 10, 2016

Jill Fiedler-Kelly Named Fellow of ISoP

Jill Fiedler-Kelly Named Fellow of ISoP

Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More

August 25, 2016

Simulations Plus Releases PKPlus™ Version 1.0

Simulations Plus Releases PKPlus™ Version 1.0

Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More

2014
December 9, 2014

First Commercial Simulx Version

First Commercial Simulx Version

Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More

October 21, 2014

MembranePlus™ Version 1.0 Released

MembranePlus™ Version 1.0 Released

Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More

September 2, 2014

Cognigen Corporation Becomes a Subsidiary of Simulations Plus

Cognigen Corporation Becomes a Subsidiary of Simulations Plus

Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More

July 7, 2014

Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”

Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”

Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More

2013
March 4, 2013

Ted Grasela Awarded With The Gary Neil Prize from ASCPT

Ted Grasela Awarded With The Gary Neil Prize from ASCPT

Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More

2012
January 9, 2012

DILIsym® Version 1A Released

DILIsym® Version 1A Released

DILIsym® Version 1A was released on January 2012. Learn More

2011
October 3, 2011

First commercial Monolix® Version 1.0

First commercial Monolix® Version 1.0

Monolix® Version 1.0 was released on October 2011. Learn More

2009
July 7, 2009

Simulations Plus Named to Fortune Small Business FSB 100 List

Simulations Plus Named to Fortune Small Business FSB 100 List

Simulations Plus has been named to the ninth annual Fortune Small Business FSB 100 list of the fastest-growing small public companies in America. Learn More

2005
February 9, 2005

DDDPlus™ 1.0 Released

DDDPlus™ 1.0 Released

Simulations Plus released version 1.0 of DDDPlus™, a simulation of in vitro dissolution experiments for formulation scientists in the pharmaceutical industry on February 2005. Learn More

January 4, 2005

ADMET Predictor™ 1.0 Released

ADMET Predictor™ 1.0 Released

Simulations Plus released version 1.0 of ADMET Predictor™, formerly known as QMPRPlus™ on January 2005. Learn More

1999
July 1, 1999

Simulations Plus Listed on The NASDAQ

Simulations Plus Listed on The NASDAQ

In 1999, Simulations Plus listed on the NASDAQ (American Stock Exchange) under the symbol SLP.

1998
July 1, 1998

GastroPlus® Version 1.0 Released

GastroPlus® Version 1.0 Released

Simulations Plus releases its flagship PBPK modeling and simulation, GastroPlus®, in July 1998. Learn More

1996
July 1, 1996

Simulations Plus Incorporated in Lancaster, California

Simulations Plus Incorporated in Lancaster, California

Simulations Plus incorporated in Lancaster, California in July 1996.